Changes in oxidized lipids drive the improvement in monocyte activation and vascular disease after statin therapy in HIV

Abstract

Rosuvastatin decreases oxLDL levels early after initiation and is associated with decreased monocyte activation. Early improvement in oxLDL is linked with improved CIMT in treated HIV infection.